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  
Summary 
 Medical device (MD) is a large number of types, more than 300, 000 products in Japan, 
so the evaluation of safety, efficacy, and effectiveness has a high diversity. There is a 
major difference of recognition in value of a MD among a manufacturing company and 
clinicians including doctors, nurse, and technician. Clinicians believe that the efficacy of 
MD is determined by the overall clinical outcome rather than the performance of the 
product itself. However, it is not required to overall clinical outcome for many of 
controlled MDs in the new registration.  In this thesis, I examined the efficacy of two 
MDs in the area of emergency and critical care medicine by post-marketing study.  
  
 Summary of post-marketing study 1  
Background: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is one 
of the ultimately invasive procedures for managing a non-compressive torso injury. Since 
it is less invasive than resuscitative open aortic cross clamping, its clinical application is 
expected. Methods: We retrospectively evaluated the safety and clinical feasibility of 
REBOA (intra-aortic occlusion balloon; MERA, Tokyo, Japan) using the Seldinger 
technique to control severe hemorrhage. Of 5,230 patients admitted to our trauma center 
  
in Japan from 2007–2013, we included 24 who underwent REBOA primarily. The 
indications for REBOA were a pelvic ring fracture (PRF) or hemoperitoneum with 
hemodynamically instability and impending cardiac arrest. Emergency hemostasis was 
performed during REBOA in all patients. Results: All 24 patients had a blunt injury, the 
median age was 59 (interquartile range, 41–71 years), median injury severity score was 
47 (37–52), 30-day survival rate was 29.2% (n = 7), and median probability survival rate 
was 12.5%. Indications for REBOA were hemoperitoneum and PRF in 15 cases and 
overlap in 8. In 10 cases of death, the balloon could not be deflated in 5. In 19 cases in 
which the balloon was deflated, the median duration of aortic occlusion was shorter in 
survivors than in deaths (21 min vs. 35 min, P = 0.05). The mean systolic blood pressure 
was significantly increased by REBOA (from 53.1 ± 21 mmHg to 98.0 ± 26.6 mmHg, P 
< 0.01). There were 3 cases with complications (12.5%)—1 external iliac artery injury 
and 2 lower limb ischemias in which lower limb amputation was necessary in all cases. 
Acute kidney injury developed in all 3 cases, but failure was not persistent. Conclusions: 
REBOA appears to be feasible for trauma resuscitation and may improve survivorship. 
However, the serious complication of lower limb ischemia warrants more research on its 
  
safety. 
 
 Summary of post-marketing study 2 
The mortality rate associated with septic shock in an intensive care unit (ICU) remains 
high, with reported rates ranging from 30% to 50%. In particular, Gram-negative bacilli 
(GNB), which induce significant inflammation and consequent multiple organ failure, are 
the etiological bacterial agent in 40% of severe sepsis cases. Hemoperfusion using 
polymyxin B-immobilized fiber (PMX), which adsorbs endotoxin, is expected to reduce 
the inflammatory sepsis cascade due to GNB. However, the clinical efficacy of this 
treatment has not yet been demonstrated. Here, we aimed to verify the efficacy of 
endotoxin adsorption therapy using PMX through a retrospective analysis of 413 patients 
who received broad spectrum antimicrobial treatment for GNB-related septic shock 
between January 2009 and December 2012 in 11 ICUs of Japanese tertiary hospitals. 
After aligning the patients' treatment time phases, we classified patients in two groups 
regarding whether PMX hemoperfusion (PMXHP) therapy was or was not administered 
within 24 hours after ICU admission (PMXHP group: n = 134, conventional group: n = 
279). The primary study endpoint was the mortality rate at 28 days after ICU admission. 
 
The mean age was 72.4 (standard deviation: 12.6) years and the mean of Sequential Organ 
Failure Assessment (SOFA) scores at ICU admission was 9.9 (3.4), respectively. The 
infection sites included intra-abdominal (38.0%), pulmonary (18.9%), and urinary tract 
(32.2%), and two thirds of all patients had GNB-related bacteremia. Notably, the 
mortality at 28 days after ICU admission did not differ between the groups (PMXHP: 
29.1% vs conventional: 29.0%, P = 0.98), and PMXHP therapy was not found to improve 
this outcome in a Cox regression analysis (hazard ratio = 0.878; 95% confidence interval, 
0.61–1.24, P = 0.46). We conclude that PMX-based endotoxin adsorption did not have an 
effect on the mortality of patients with septic shock due to GNB. 
 As noted above, I believe that it was possible for re-evaluation of MD to select the 
appropriate study design depending on characteristics of the device in the real world. 
Clinical research of the post-marketing study performed in this thesis would contribute to 
the safety assurance of MDs in high-risk patients with a severe condition. The fair 
evaluation of MDs by health care worker is sufficiently possible, and it calls for a platform 
with an appropriate scale to resolve a number of clinical questions in the realistic medical 
field. 
 
  
Chapter 1 
Overall background 
 Medical device (MD) holds a large number of types, more than 300, 000 products in 
Japan, as compared to the drug in 17,000 products, therefore the evaluation of safety, 
efficacy, and effectiveness displays has a high diversity. 
 In general, except for a special bioabsorbable material, the shape of MD is universal and 
its action is either mechanical, and electrical, or physical. Therefore, evaluation of MD, 
unlike drugs, is carried out by determining the efficacy of the overall clinical outcome 
rather than the performance of the product itself. However, efficacy of MD is dependent 
on the user's experience and skill and it must be evaluated by incorporating a variety of 
factors. There is a major difference of recognition in value of a MD among manufacturing 
companies and clinicians including doctors, nurses, and technicians. Clinicians believe 
that the efficacy of MD is determined by the overall clinical outcome rather than the 
performance of the product itself. However, it is not required to overall clinical outcome 
for many of controlled MDs in the new registration.  
 In the clinical trials of MDs, some cases were evaluated only for product performance 
 
rather than overall clinical outcome. For this reason, it is necessary to re-evaluate the true 
clinical value of a MD in post-marketing period. As pre-clinical trials were carried out 
only in a limited number of cases in a limited observation period, post-marketing study 
is carried out to confirm the safety. The post-marketing study collects clinical data in the 
realistic world to determine the validity of use for special cases or off-label cases. Medical 
professionals and patients can obtain long-term data and information about rare adverse 
events through the post-marketing study, which was not obtained through clinical trials. 
This process will improve the quality of information and ensure a highly transparent 
medical care provided to patients. In addition, it will also help in positioning of the 
treatment with the new MD by comparing it with the existing treatment. The following 
are the three advantages of the post-marketing study: (i) strengthening and re-evaluation 
of the evidence, (ii) confirming the clinical efficacy and safety with a high precision, and 
(iii) providing basic information to design clinical trials for the next generation of MDs. 
It proves to be important for the public health that such a post-marketing study is available 
to assure a highly effective treatment. 
 In this thesis, two post-marketing studies for the efficacy of MDs in the area of 
 
emergency and critical care medicine were conducted and their validity was examined. 
The significance of re-evaluating the efficacy of the existing MDs is discussed throughout 
the study series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Evaluation of the Safety and Feasibility of Resuscitative Endovascular 
Balloon Occlusion of the Aorta 
 
Background 
 Hemorrhagic shock is not controlled easily and is a leading cause of death in trauma 
patients worldwide [1]. Bleeding control, the maintenance of tissue oxygenation with 
fluid resuscitation, the correction of coagulopathy, and the management of normothermia 
remain therapeutic mainstays for critically injured patients with hemorrhagic shock.  
Recently, damage control resuscitation (DCR) brought a dramatic change to the 
resuscitation of severe trauma patients with hemorrhagic shock [2]. During DCR, if 
cardiac arrest is imminent because of an uncontrolled hemorrhage, open aortic cross 
clamping via resuscitative thoracotomy may be selected. In particular, this technique is 
used in patients with life-threatening penetrating injuries [3-5]. However, the procedure 
is extremely invasive, and the incidence of complications rises even if survival is possible. 
Conversely, several clinical reports on resuscitative endovascular balloon occlusion of 
 
the aorta (REBOA) for trauma patients with difficult resuscitation due to hemorrhagic 
shock have demonstrated advances in endovascular technology [6-8]. The original 
method for REBOA was known as intra-aortic balloon occlusion [9] and was first 
reported during the Korean War in 1954 [10]. The aim of REBOA is to maintain the brain 
and coronary circulation and to control hemorrhaging from the injured organ temporarily 
by occluding it with balloon inflation of the aortic lumen.  
 Subsequently, some large animal experiments [11-15] and clinical series [6,7,9] on the 
effectiveness of REBOA have been reported. Recently, the effectiveness of aortic balloon 
occlusion in hemorrhage control of a cesarean section during placental presentation16 
and endovascular treatment of ruptured abdominal aortic aneurysms [17,18] have been 
reported. Based on these studies, the possibility of using REBOA for non-compressive 
torso trauma has been suggested. A non-compressive torso trauma includes 
hemoperitoneum and pelvic ring fractures (PRF), in which hemostasis is difficult to 
achieve with simple manual compression. The general indications for REBOA are these 
aforementioned injuries and an unstable hemodynamic state. 
 REBOA is one of the invasive procedures for managing severe subphrenic non-
 
compressive torso injuries along with resuscitative open aortic cross clamping via 
resuscitative thoracotomy [19]. Nevertheless, the clinical feasibility and safety of 
REBOA is unclear; therefore, we aimed to evaluate its efficacy, safety, and clinical 
feasibility. 
 
Methods 
Study Setting 
 We conducted a retrospective study between January 2007 and December 2013 at the 
Shock and Trauma Center of Nippon Medical School Chiba Hokusoh Hospital, which is 
similar to a level 1 trauma center in the United States. This study was approved by the 
hospital’s ethics committee. 
Procedure for Resuscitative Endovascular Balloon Occlusion of the Aorta 
 The indications for REBOA were hemoperitoneum or PRF with impending cardiac 
arrest. In this study, the criteria for using REBOA included a state of no fluid 
responsiveness and a sustained systolic blood pressure of <90 mmHg. If there was no 
pulse, REBOA was prioritized over resuscitative thoracotomy even before the hospital 
 	
setting [19], because it is difficult to puncture the femoral artery. After resuscitative 
thoracotomy was rapidly performed, we converted to REBOA, because it was possible to 
finely adjust the endovascular occlusion. Thus, REBOA had primary and secondary uses. 
Typically, even if there has been circulatory failure, vascular access is preferred when 
using REBOA emergently. 
 Emergency hemostasis, including external fixation and retroperitoneal packing for 
PRF or urgent laparotomy to control bleeding, was performed during the REBOA 
procedure in all patients. If necessary, multiple hemostatic procedures (e.g., laparotomy 
and angiography) were used. Angiography was possible to restart the aortic blood flow 
to partly deflate the balloon. The device for REBOA was an aortic occlusion balloon, 
which contains the balloon catheter and sheath (intra-aortic occlusion balloon; MERA, 
Tokyo, Japan) (Figure 1). The size of the sheath is 10 French (Fr), and the insertable 
length of the catheter is 685 mm; it is reinforced by an internal metal wire. The length of 
the balloon tip is 65 mm with a maximum diameter of 30 mm. The insertion procedure 
was performed by trauma surgeons or emergency physicians. On occasion, ultrasound-
guided or blind puncture and the cut-down method were optionally employed. The initial 
 

position of the balloon catheter was placed blindly into Zone I [20], and then the position 
was adjusted by fluoroscopic angiography or portable radiography (Figure 2). In addition, 
intravascular placement was confirmed during hemostatic angiography or in the surgical 
field. Inflation of the aortic balloon was performed using 20 mL of normal saline, and the 
balloon was deflated gradually with careful hemodynamic monitoring. The sheath was 
removed after vascular repair by exposing the femoral artery when it was decided that 
REBOA was no longer necessary. 
 At our institution, there is no technical qualification regarding the implementation of 
REBOA; however, attending emergency physicians and surgeons in the emergency room 
are skilled in vascular puncture procedures. In addition, the anesthesiologist was 
contracted for the perioperative management of REBOA. For technique acquisition, 
he/she was skilled in femoral artery blood vessel puncture and was familiar with the 
anatomy of the large blood vessels in elective angiography. This experience is necessary 
for managing the aortic balloon based on aortic pathophysiology. Additionally, it is 
necessary to understand the massive transfusion protocol and hemostasis procedure. 
Along with such knowledge and experience, it is possible to use the REBOA system after 
 
having hands-on training under a senior physician’s supervision. 
Data Analysis 
 Figure 3 shows the study flow chart. Inclusion criteria in this study were patients aged 
≥18 years who underwent the implementation of REBOA. Of 5,230 trauma patients 
admitted during the study period, 52 who underwent REBOA for total resuscitation and 
24 who underwent REBOA primarily were included in the analysis. Twenty-eight who 
underwent REBOA secondarily after open aortic cross clamping via resuscitative 
thoracotomy were excluded. Patients were divided into the 24 h survivor group (group 1: 
n = 14) and the non-survivor group (group 2: n = 10). Their clinical and laboratory data 
were retrieved from their medical records and were compared. The clinical assessment 
data included the patients’ age, sex, mechanism of injury, initial vital signs on arrival to 
the emergency department (ED), injury severity score (ISS), site of injury, type of surgical 
procedure, time from hospital admission to balloon inflation, and duration of aortic 
occlusion with balloon inflation. The 24-h and 30-day survival rates were recorded and 
evaluated. Laboratory data included the base deficit and lactate, which were recorded on 
ED arrival. The probability survival rate was based on the previously described trauma-
  
related injury severity score methodology, and it was calculated and evaluated by the 
prediction formula [21,22]. 
 Surgical hemostasis and the volume of red blood cells (RBC) within 24 h after 
admission were recorded. The time course associated with REBOA was calculated. Other 
outcome measures were the incidence of complication, vascular injury due to the insertion 
of REBOA, limb ischemia and amputation, spinal cord ischemia, acute kidney injury 
(AKI), and multiple organ failure (MOF). AKI was defined using the Risk, Injury, Failure, 
Loss of kidney function, and End-stage kidney disease (RIFLE) criteria [23]. MOF was 
defined using the sequential organ failure assessment score (SOFA) system [24]. The 
maximum SOFA score of each organ with ≥3 points was defined as organ failure, and 
MOF was defined as ≥2 organ failures. 
Statistical Methods 
 The demographics and clinical parameters were assessed between the groups. 
Significant differences for the median and prevalence estimates were determined using 
the chi-squared test and the Kendall and Mann-Whitney U tests for categorical and 
continuous variables, respectively. P values <0.05 were considered significant. All the 
   
statistical analyses were performed using SPSS, version 19.0 (IBM, Chicago, IL, USA). 
 
Results 
 Table 1 shows all the patients’ characteristics. All 24 patients had a blunt injury, the 
median age was 59 years (interquartile range, 41–71 years), and the median injury 
severity score was 47 (range, 37–52). The probability survival rate for all the patients was 
<0.5 with a median rate of 12.5%. The survival rate of >24 h from admission was 58.3% 
(n = 14), and the 30-day survival rate was 29.2% (n = 7). The indications for REBOA 
were hemoperitoneum and PRF in 15 cases, and 8 cases included both indications. Only 
one patient was a trauma flanked by instrument of pelvic. Initially, PRF was suspected, 
but it was a left femoral artery injury. Percutaneous puncture was used in 23 cases, while 
insertion techniques and surgical cut-down were performed in 1 case. 
 Table 2 compares the patients’ characteristics, clinical data, and treatment and 
complications between groups 1 and 2. The ISS and the site of injury were similar in both 
groups. The proportion of traffic accidents and pedestrian injuries in group 1 was greater 
than that of group 2. The initial state of consciousness in group 1 was significantly better 
  
than that in group 2. Other clinical findings at the time of ED arrival were almost similar 
between the groups. The type of hemostasis revealed no difference between the groups, 
and there was no statistically significant difference in the amount of PRBCs within 24 h 
after admission.  
 The time from ED arrival to inflate the aortic balloon and perform vascular puncture 
was 20 min in all the cases. The aortic balloon could not be deflated in 5 of 10 cases in 
group 2. In the remaining 19 cases in which the aortic balloon was deflated, the median 
duration of aortic occlusion, the time from inflation of the aortic balloon to deflation, was 
shorter in group 1 than that in group 2 (21 min vs. 35 min, P = 0.05), even though it was 
not significantly different (Table 2). Three patients arrested before the implementation of 
REBOA after ED arrival. One of these patients temporarily recovered, but all three 
patients died in the hospital.  
 With regard to systemic complications, there were nine cases of AKI. Only one case 
had AKI alone. Five of 9 cases had an AKI grade of failure according to the RIFLE 
criteria. There were also 9 cases of MOF (Table 2). Complications of the lower 
extremities associated with vascular puncture were observed in 3 cases—lower limb 
  
ischemia in 2 and external iliac artery injury in 1, all of which required lower limb 
amputation. In one case of vascular injury, the 10 Fr sheath was inserted after multiple 
blind punctures in an obese male. When the angiography for PRF revealed a simultaneous 
vascular injury, its repair had been performed; however, lower limb ischemia that required 
amputation 2 days later was inevitable. One patient with ischemia had open bilateral 
femoral fractures with an extensive soft tissue injury that progressed to limb ischemia and 
resulted in amputation of the puncture side of the lower limb 3 days after admission. 
Another patient with ischemia had an open pelvic fracture, and the balloon catheter was 
inserted into the femoral artery directly through the damaged part of the groin. After 
emergent arterial embolization was performed for bleeding, the lower limbs were cut 
from the hip. AKI developed in all 3 cases, but failure was not persistent. None of the 
survivors had spinal cord ischemia or arterial thrombosis, and there were no 
complications related to sheath removal. 
 
Discussion 
 With regard to damage control hemostasis and resuscitation for severe trauma patients 
  
with hemorrhagic shock, several additional techniques have been sought to obtain 
temporary hemostasis. REBOA closely applies to this requirement, and the clinical 
probability of its effects is expected. In the present report, we described the complications 
and procedures associated with REBOA, and we showed its clinical safety and feasibility, 
which were insufficiently described in previous reports [6,7].  
 Since Holcomb proposed the concept of DCR in 2007 [2], aggressive plasma 
transfusion therapy using the massive transfusion protocol, permissive hypotension 
during hemostasis, and body temperature management have been accepted worldwide. 
Simultaneously, damage control surgery has also advanced, and the technique of 
temporary hemostasis has also been improved. Nevertheless, we still encounter many 
severe trauma patients whose hemorrhages cannot be easily controlled. It would be 
difficult to perform additional treatments (e.g., surgical hemostasis or arterial 
embolization with transfer to the operating room [OR] or interventional radiology [IR] 
room) despite unstable vitals. For such a situation, REBOA is a good approach with the 
possibility of solving this dilemma. 
 According to our findings, after temporary bleeding control using thoracotomy or 
  
laparotomy with REBOA in the ED, 12 patients were stable enough to move to the IR 
room and 9 were stable enough to move to the OR. To avoid cardiac arrest during 
transport to the hospital, blood flow blocking on the central side from the bleeding point 
is the most effective method. By using REBOA, the 30-day survival rate greatly exceeded 
its predictions, as it was more than double the calculated probability of survival. However, 
although the 24 h survival rate was >50%, MOF in the intensive care unit after hemostasis 
procedures was still a serious issue. Two-thirds of the patients who survived >24 h in this 
study had MOF. If we overcome this, the clinical efficacy of REBOA will be evaluated 
as the ultimate procedure for obtaining a long-term survival. Therefore, to truly evaluate 
the effectiveness of REBOA, it would be reasonable to evaluate early survival (i.e., the 
survival rate of >24 h from admission) without the influence of MOF.  
 In this study, the main indication for REBOA was non-compressible torso trauma with 
impending cardiac arrest due to hemorrhagic shock. In particular, we recognized that 
unstable PRF with hemodynamic instability is an optimal target for REBOA. PRF cases 
accounted for about 60% in this study, and they were all multiple traumas. Although the 
effect of REBOA for temporal hemostasis is theoretically poor in thoracic trauma, 
  
REBOA contributed to maintaining tissue perfusion of the brain and heart to avoid 
dysoxia. Even if there was no statistical significance in the base deficit and lactate 
between the groups, tissue perfusion after REBOA application in the 24-h survival group 
may have improved because of the change in systolic blood pressure (data not shown). 
As a result, it was reasonable to use the REBOA in patients with multiple traumas. 
However, the decision to employ it was always difficult, and if necessary, the earlier 
adoption of REBOA was better. The REBOA implementation required about 20 min to 
inflate the aortic balloon from the patients’ arrival, but there were three cases of cardiac 
arrest before its employment. Therefore, the time until the decision for using REBOA is 
most essential. In addition, if we can recognize that the victim has obvious shock and 
massive transfusion is predicted [25], it will also be necessary to prepare the REBOA 
induction. The prophylactic use of this technique for specific injuries of hemorrhagic 
shock may be expected in the future, but we have to overcome the risk of excessive 
invasiveness. Given such an effectiveness of REBOA in this study, it would be clinically 
feasible to introduce REBOA for patients with severe hemorrhagic shock. 
Insertion of the catheter for the occlusion balloon was performed in the ED. Primary 
  	
positioning was blindly performed with manual estimation, and the intravascular 
placement of the catheter was confirmed by portable radiography. We aimed the aortic 
balloon at Zone I initially; [20] however, the success rate was unclear because all the 
imaging findings could not be obtained. Our catheter was reinforced with metal and was 
devised to not bend. Typically, it is reasonable for it to be placed in Zone I; however, if 
the vessel is meandered by arteriosclerosis, the risk of arterial injury due to the 
implementation of REBOA may increase. We confirmed the running of the blood vessels 
with a guide wire in such cases. There was no damage to the aorta in our case series. 
However, there was one case of arterial injury in the pelvic cavity, which was considered 
to be caused by the multiple punctures required for placing the guide wire in an obese 
patient. In recent years, ultrasound-guided vascular puncture with echo has become a 
standard procedure because of the spreading and progress of small movable devices 
[26,27]. Because it was necessary to perform a quick puncture for REBOA employment 
just before cardiac arrest, the process of vascular identification by ultrasound was often 
omitted. Since a safe arterial access and balloon management are required to achieve a 
good outcome, endovascular skills should be learned through a well-designed course (e.g., 
  

the Endovascular Skills for Trauma and Resuscitative Surgery Course) [27]. However, 
there are no public qualifications for REBOA and the training course on the balloon 
catheter in Japan. Since the REBOA procedure is used, only the basic skills of arterial 
puncture are required, and if one has the additional knowledge and experience with 
balloon management, it is not difficult. However, it is necessary to perform hemostasis in 
parallel with REBOA, and all the resuscitation team members should be aware of this 
concept. 
 Our series had major complications, which included lower limb ischemia and AKI 
induced by systemic ischemia associated with REBOA. To avoid these complications, 
earlier deflation of the aortic balloon must be performed after immediate hemorrhage 
control via a surgical or interventional radiological approach. Fortunately, there were no 
cases of thromboembolic or spinal cord ischemia, which are a concern with open aortic 
clamping via resuscitative thoracotomy. However, the number of cases was small in this 
report, and a more comprehensive evaluation of these complications is warranted. The 
time from inflation to deflation of the aortic balloon in 24-h survivors was shorter than 
that in non-survivors. It was suspected that reperfusion injuries due to systemic ischemia 
  
would lead to death. In experiments with swine, Morrison and colleagues reported that a 
longer aortic inflation time increased the release of interleukin-6, incidence of acute 
respiratory distress syndrome, and use of vasopressors [15]. In the present case series, 7 
of 14 patients in the 24-h survival group died. The cause of death included persistent 
hemorrhage in 1, head injury in 1, and MOF in 5. In another experiment with swine [14], 
the survival threshold of aortic occlusion was 40 min, but this evaluation only described 
early death during the resuscitation period and MOF was not considered. Therefore, the 
simplistic adaptation to humans is dangerous, and it would be realistic that the median 
occlusion time of the 24-h survival group was about 20 min. Hemostasis in the golden 
time of 20 min has emerged as a challenge for the future.  
 There are some limitations to this study. First, the study was conducted at a single 
center with a small sample population, and the study design was retrospective. This is the 
result of careful patient selection, but the potential number of patients would have been 
more. Thus, there was obviously selection bias. In particular, there were many secondary 
implementations of REBOA, because it was a priority in resuscitative thoracotomy for 
open aortic clamping due to the time shortening and impending cardiac arrest. This 
 
trauma care process has been implemented as a facility policy. For comparison, 
resuscitative thoracotomy and REBOA were considered inappropriate because the 
patients’ conditions were significantly different between the two procedures. Fifteen 
patients who underwent REBOA secondarily after resuscitative thoracotomy (15/28, 
53.6%) had cardiopulmonary arrest before the procedure. In contrast, among our study 
patients, only three patients (3/24, 12.5%) had prior cardiopulmonary arrest. This 
apparent difference can lead to erroneous conclusions. Since the background of the two 
groups in the present study was not the same, the number of cases would have been more 
necessary. Second, the balloon catheter sets are only sold in Japan. Therefore, it is 
unknown whether patients of different races and physique in other countries would be 
compatible with this balloon catheter. Third, we did not evaluate the skills of the operator. 
There were no criteria for skills in the implementation. In the current study, an attending 
trauma surgeon and emergency physician managed the REBOA. Since complications 
cannot be avoided even with experienced staff, the acquisition of standard procedures is 
extremely important [27]. The weakest point in the evaluation of feasibility of REBOA is 
that this technology has fallen into disuse once in the world. Since the 1980s [9,28], some 
  
reports describe that it was left behind until endovascular treatment progressed. 
Fortunately, advances in trauma care have been achieved since this period, and the door 
to REBOA has remained open. There is always swingback in medical technology [29]. It 
takes decades for evidence to be established, and recommendations for treating critical 
patients change with the times. REBOA may also follow such a course; however, it is 
expected to be a real innovation for enhancing safety, because the technology 
encompasses a fairly simple theory. 
 In conclusion, REBOA was a feasible adjunct for supporting definitive hemostasis of 
non-compressive torso trauma in our series. However, it must be noted that potential 
complications of lower limb ischemia and vascular injury exist, and there is a high risk 
of MOF after deflation of the aortic occlusion. The safety implementation of REBOA will 
be established through rapid conduct for severe hemorrhagic shock, appropriate puncture 
and placing, and immediate balloon deflation. A future multicenter prospective study in 
a reasonable adaptation setting is needed to expand on this innovative approach. 
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Tables and Figures 
Table 1. All patient characteristics 
Characteristics Patients (n=24) 
Age (years) 59 (41-71) 
Male/ female 13 / 11 
Injury severity score 47 (37-52) 
Revised trauma score 4.41 (2.93-5.77) 
Probability survival rate 12.5 (2-40) 
Blunt trauma, no (%) 24 (100) 
Hemoperitoneum, no (%) 15 (62.5) 
Pelvic ring fracture, no (%) 15 (62.5) 
Time from ED arrival to balloon inflation  (min) 20 (13 – 72) 
24 hours-survival rate 58.3 % 
30 days-survival rate 29.2 % 
 
Data are presented as median values with interquartile range or as number (%).  
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Table 2. A comparison of the patients’ characteristics, clinical data, and treatment between 
groups 1 and 2 
Variable Group 1 
(n = 14) 
Group 2 
(n = 10) 
P value 
Age (years) 65 (41–73) 47 (32–65) 0.16 
Male/female 6/8 7/3 0.36 
ISS 40 (34–50) 50 (45–54) 0.06 
Site of injury, no (%) 
Head AIS ≥3 3 (21.4) 5 (50.0) 0.14 
Chest AIS ≥3 6 (42.9) 8 (80.0) 0.06 
Abdominal AIS ≥3 11 (78.6) 8 (80.0) 0.93 
Extremities AIS ≥3 8 (57.1) 6 (60.0) 0.88 
Hemoperitoneum 9 (64.3) 6 (60.0) 0.83 
Pelvic ring fracture 7 (50.0) 8 (80.0) 0.13 
Mechanism of injury, no (%) 
Traffic accident 6 (42.9) 1 (10.0) 0.31 
Fall 0 (0) 4 (40.0) 
Pedestrian 6 (42.9) 2 (20.0) 
Other 2 (14.3) 2 (20.0) 
ED admission vitals and laboratory data 
Systolic blood pressure (mmHg)  75 (59–96) 57 (31–89) 0.13 
Heart rate (bpm)  125 (83–150) 115 (84–147) 0.74 
Glasgow coma scale  10 (6–14) 3 (3–6) 0.01 
Base deficit (mmol/L) -8.7 (-15.7 to -6.0) -16.0 (-19.3 to -11.4) 0.09 
Lactate (mmol/L) 6.9 (4.2–10.8) 9.4 (5.8–11.4) 0.21 
Hemostasis procedures, no (%) 
Laparotomy  6 (42.9) 4 (40.0) 0.88 
Retroperitoneal packing 2 (14.3) 0 0.21 
TAE 8 (57.1) 5 (50.0) 0.79 
Volume of RBC within 24 hr 
after admission (mL) 
6,160 (3,360–8,680) 3,640 (1,400–8,400) 0.22 
Duration of aortic occlusion (min) 21 (13–26) 35 (28–35) 0.05 
 
Continuation of Table 2 
Variable 
Group 1 
(n = 14) 
Group 2 
(n = 10) 
P value 
Complications, no (%) 
AKI: Risk/injury/failure 3 (21.3)/1 (7.1)/5 (35.7) -  
MOF 9 (64.2) -  
Lower limb ischemia 2 (14.2) 0 0.21 
Arterial injury due to puncture 1 (7.1) 0 0.38 
Lower limb amputation 3 (21.3) 0 0.11 
Group 1 is the 24 h survivor group (n = 14), and group 2 is the 24 h non-survivor group 
(n = 10). The data are presented as median values with an interquartile range or as a 
number (%).  
 
ISS, injury severity score; AIS, abbreviated injury scale; ED, emergency department; 
TAE, trans-arterial embolization; PRBC, packed red blood cell; AKI, acute kidney injury; 
MOF, multiple organ failure. 
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Figure 1. The device for resuscitative endovascular balloon occlusion of the aorta 
(REBOA) and the intra-aortic occlusion balloon (IABO; MERA, Tokyo, Japan). 
 
The product is encapsulated in the IABO insertion set. A) The aortic balloon and the 
double-lumen catheter. B) The 10 French sheath, two dilators, guide wire, and seldinger 
needle. The inner lumen of the double lumen catheter is furnished with a stylet made of 
stainless steel. The cylindrical shaped balloon is made of a polyurethane material. 
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Figure 2. Position confirmation of the balloon catheter by fluoroscopy or portable 
radiography.  
 
A) A case in which the catheter was placed in Zone I, and the position was confirmed at 
the start of angiography for the pelvic fracture after laparotomy. B) A case in which the 
catheter was placed in Zone III, and the position is confirmed in the emergency 
department during external fixation of the unstable pelvic ring fracture. The black arrows 
indicate the tip of the catheter. 
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Figure 3. Study flow chart. 
 
REBOA, resuscitative endovascular balloon occlusion of the aorta 
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• Implementation of REBOA
• Exclusion: cardio pulmonary arrest at hospital arrival  
Primary use of REBOA: n = 24
Exclusion Secondary use of REBOA 
after open aortic clamping via 
thoracotomyn = 28
Figure 1
24 h survivor group
(group 1: n = 14)
Non- survivor group 
(group 2: n = 10)
 
Chapter 3 
Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients 
with septic shock caused by Gram-negative bacillus infection 
 
Background 
 The incidence of septic shock (SS), a critical and potentially fatal illness characterized 
by an excessive biological reaction against an infections pathogenic microorganism, is 
increasing worldwide [1]. Since 2004, international guidelines for management of severe 
sepsis and septic shock (surviving sepsis campaign) have advanced the standardization 
of primary care for sepsis [2], and SS-related mortality rates have been steadily decreasing 
in intensive care units (ICUs) [3]. However, the clinical outcomes of SS vary widely, with 
reported 28-day mortality rates ranging from 30% to 50% [3].  
 Currently, Gram-negative bacilli (GNB) are the etiological bacterial agent in 40% of 
SS cases [1], and are known to cause excessive inflammatory reactions that may lead to 
multi-organ failure [4]. Unfortunately, GNB is also a major causative organism of 
nosocomial infections, and the resulting increase in drug resistance has led to treatment 
challenges [5]. The GNB outer membrane component endotoxin is a well-known, typical 
 
pathogen-associated molecular component that can induce inflammation [6], and as early 
as a few decades ago, GNB-induced SS was described as endotoxin shock and considered 
to be a more critical condition [7, 8]. These findings have led to considerable research 
regarding the potential of endotoxin as a therapeutic target [9].  
 In the 1980s, this endotoxin-related research led to the development of a polymyxin B-
immobilized fiber column (PMX: Toraymyxin®; Toray Medical Co., Ltd., Tokyo, Japan), 
which utilizes the ability of polymyxin B to bind lipid A within the major endotoxin 
effector site. The endotoxin adsorption efficacy of PMX, which has been used in clinical 
applications in Japan since 1994 [10, 11], has been demonstrated both in vitro and in vivo, 
and this material has since been used with the hope that it could suppress the GNB-related 
inflammatory cascade [10]. More recently, PMX has been used to treat intra-abdominal 
infection in several countries.  
 Although a high serum endotoxin levels is associated with a poor prognosis in patients 
with SS, there is no clear evidence regarding the clinical effect of endotoxin adsorption 
therapy with PMX hemoperfusion (PMXHP) on survival [7, 12, 13]. In a 2007 systematic 
review of PMXHP [11], Cruz et al. reported that the arterial pressure and pulmonary 
 
oxygenation (PaO2 / FiO2 ratio; P/F ratio) were improved and the mortality was 
decreased with the implementation of PMXHP (odds ratio [OR] = 0.53, 95% confidence 
interval: 0.43–0.65). In contrast, recent publications by Cruz et al. in 2009[14] and Payen 
et al. in 2015 [15] reported no significant decreases in mortality among patients with 
abdominal sepsis. Similar results were observed among Japanese patients with lower 
gastrointestinal perforation in a propensity-matched analysis of nationwide inpatient 
insurance data [16]. However, the limitation of all of these previous reports was the lack 
of certainty regarding the GNB infection status in all target patients.  
 We conducted a multi-center study with the intent to verify the following hypothesis: 
after achieving infection site control and implementing broad-spectrum antibacterial 
treatment, the 28-day mortality rate would improve with the addition of PMXHP as an 
adjuvant therapy in patients with SS due to GNB. 
 
Methods 
Study setting 
 We conducted a retrospective study at 11 ICUs of Japanese tertiary hospitals. Before 
 
data collection, the study protocol was reviewed and approved by the ethics committee 
of each institution. The trial was registered in the University Hospital Medical 
Information Network Clinical Trial Registry (UMIN-CTR ID: UMIN000012748). 
Data collection 
 Each investigator was provided a comprehensive manual that described the data 
collection requirements and definitions of variables. Case report forms were uploaded to 
the study website via the internet. Case registration was mandatory to ensure correct 
alignment of the treatment order and time-phase and adjustment of confounding factors. 
Data management was performed by at an independent data center at the University of 
Tsukuba (CREIL Center, Ibaraki, Japan). 
 The inclusion criteria were patients admitted in ICUs from January 2009 to December 
2012, an age ≥18 years and SS resulting from GNB, as detected from clinical specimens. 
Sepsis was diagnosed according to the 2008 Surviving Sepsis Campaign Guidelines. In 
addition, SS was defined as hypotension (systolic blood pressure <90 mmHg) at the start 
of the medical intervention or an elevated lactate level (>4 mmol/L). Microbial 
confirmation of GNB required the isolation of pathogens from any clinical culture. The 
 	
study excluded the patients of non-resuscitate status.  
 Patients received broad-spectrum antimicrobial treatment, if needed, surgical 
intervention for source control before ICU admission. After aligning each patient's 
treatment time phase, we classified patients into two groups depending on the 
administration of PMXHP treatment within 24 hours after ICU admission (PMXHP 
group: n = 134, conventional group: n = 279).  
 To compare patient's conditions before PMXHP therapy, the following information was 
collected: age, sex, severity of illness (e.g., APACHE [Acute Physiology and Chronic 
Health Evaluation II] II score [17], Sequential Organ Failure Assessment [SOFA] score 
[18]) pre-existing disease, comorbidities upon PMX session (e.g., all grades of acute 
respiratory distress syndrome [ARDS] defined according to the criteria of the Berlin 
definition [19], all grades of acute kidney injury [AKI] defined according to the RIFLE 
criteria [20], disseminated intravascular coagulopathy [DIC] diagnosed using the 
Japanese Association for Acute Medicine DIC scores [21], acute coronary syndrome 
[ACS]/stroke diagnosed a vascular lesion specialist, intraperitoneal abscess diagnosed 
from imaging findings), type of infection (e.g., community acquired, hospital acquired, 
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healthcare acquired), site of infection (e.g., pulmonary, intra-abdominal, urinary, soft 
tissue), vital signs, and laboratory data at the beginning of the medical intervention. 
Details of defined cultures were collected separately from blood and local samples. 
Information about treatment for comorbidities after ICU admission and specific drug 
usage was also collected. 
Implementation of PMXHP therapy 
 Decisions regarding PMXHP therapy were left to each facility. Japanese public 
insurance allows the performance of 2-hour direct hemoperfusion sessions with heparin 
administration as a basic PMXHP protocol. In the current study, this protocol has been 
adjusted for anti-coagulant drugs and the duration of direct hemo-perfusion at each 
facility. In addition, further options could be added to a subsequent session of PMXHP 
after completing the initial session. Data regarding the implementation of PMXHP, vital 
signs, and laboratory data of the patient before and after the implementation PMXHP 
therapy, were collected.  
Outcomes 
 The primary endpoint was the mortality rate at 28 days after ICU admission, and the 
 
secondary endpoints were the mortality rate at hospital discharge, duration of mechanical 
ventilation, length of ICU stay, and length of hospital stay. In addition, outcome-free days 
(e.g., ventilator-free days, ICU-free days) were determined to minimize survivor bias. 
Comorbidities after PMX session, including ARDS, AKI, DIC, ACS, stroke, and 
intraperitoneal abscess, were also recorded as clinical outcomes.  
Sample size and statistical methods  
 Based on previous studies [4, 11, 14], we assumed that in order to be clinically 
meaningful, the assumed mortality rate at 28 days for the target patient population, 40%, 
would need to be reduced to 25% after implementing PMXHP therapy. Assuming that 
PMX intervention was performed in one third of the target patients, the size needed to 
test an absolute reduction in mortality at 28 days of 15% (relative reduction of 37%) 
would be 390 patients (130 for PMXHP group and 260 for conventional group) to obtain 
a nominal two-sided p value of 0.05 and power of 85%.  
The groups were compared with respect to demographic and clinical parameters. 
Significant differences in means, medians, and prevalence estimates were determined 
using the chi-square test for categorical variables, the t test or Mann–Whitney U test for 
 
independent continuous variables, and the Wilcoxon signed rank test for paired 
continuous variables. P values <0.05 were considered significant. A Cox proportional 
hazards model adjusted for age, sex, and pre-treatment status was used for the 
multivariate analysis. All statistical analyses were performed using SPSS, version 23.0 
(IBM, New York, IL, USA). 
 
Results 
Patient characteristics 
 The mean age of patients in this study was 72.4 years (standard deviation: 12.6), and 
the mean SOFA score upon ICU admission was 9.9 (3.4). Mechanical ventilation was 
performed in 72.9% of all patients, and a third of patients underwent surgery for source 
control. The infection sites were intra-abdominal, pulmonary, and urinary tract in 38.0%, 
18.9%, and 32.2% of patients, respectively, and two thirds of all patients had bacteremia 
due to GNB.  
 Table 1 compares the patient characteristics, clinical data, and treatments of the 
PMXHP and conventional groups. Although the PMXHP group was younger than the 
  
conventional group, this difference was not significant (P = 0.06). However, the 
frequencies of comorbid AKI and DIC at the time of ICU admission differed significantly 
between the two groups (P = 0.01 and <0.01, respectively), and the frequency of 
mechanical ventilation was significantly higher in the PMXHP group (87.3% vs. 65.9% 
for the conventional group).  
 Although the distribution of infection type was homogenous, the distribution of 
infection site was somewhat heterogeneous. For example, a large proportion of patients 
in the PMXHP group had intra-abdominal infection, whereas the proportion with 
pulmonary infection was relatively small. However, both groups had similar frequencies 
of bacteremia. Furthermore, surgery for source control was more frequently implemented 
in the PMXHP group relative to the conventional group. In addition, although the 
conditions prior to treatment were similar in both groups, the severity of illness, indicated 
by the SOFA score, was significantly higher in the PMXHP group than the conventional 
group. The administration of specific treatments, including continuous renal replacement 
therapy and recombinant thrombomodulin, after ICU admission also differed 
significantly between the two groups.  
 
Outcomes 
 The primary endpoint, mortality rate at 28 days after ICU admission, did not differ 
between the two groups (PMXHP: 29.1% vs conventional: 29.0%, P = 0.98). For 
secondary outcomes, duration of mechanical ventilation and ventilator free days were 
better in the conventional group than that in the PMXHP group. The groups differed with 
regard to additional comorbidities after PMX session; specifically, DIC was more 
common in the PMXHP group, whereas ARDS and stroke were more common in the 
conventional group (Table 2). Figure 1 demonstrates that PMX treatment (hazard ratio = 
0.87; 95% confidence interval, 0.61–1.24, P = 0.464) did not improve the study outcome 
measures, according to a multivariate Cox regression model analysis; in addition, no 
inter-group differences were observed at hospital discharge. Figure 2 additionally shows 
a post-hoc subgroup analysis in which we again did not observe differences in efficacy 
and interactions in any PMXHP subgroup. 
Hemoperfusion practice 
 A total of 184 PMXHP sessions were conducted, and the actual median adsorbed time 
was 144 minutes. The standard 2 hours were not completed in 11 sessions (5.9%); in one 
 
such case, the patient fell into cardiopulmonary arrest and died during PMX treatment. 
The overall mean arterial pressure increased after PMXHP relative to the pre-treatment 
value (before PMXHP: 68[57–80] vs. after PMXHP: 76 [65–87] mmHg, P <0.01); 
however, in the initial session, deterioration in blood pressure with or without additional 
catecholamine was observed at 42.5% (57/134). No improvements were observed in the 
P/ F ratio, lactate level, or base deficit (an indicator of circulatory failure; data not shown).  
 
Discussion 
 In this study, which was conducted in tertiary care hospitals involved the current 
general level of sepsis practice in Japan, we did not observe an additional clinical benefit 
of adjuvant PMXHP therapy on mortality after the administration of broad-spectrum 
antimicrobial agents and source control among the patients with SS, in which more than 
60% presented with GNB bacteremia. Moreover, no subgroup-related differences in 
efficacy were observed in a post-hoc analysis.  
 In Japan, PMXHP therapy has been used generally for approximately 20 years [10, 11], 
and protocols have been developed at a number of large-scale facilities. However, the use 
 
of PMXHP therapy is left to the physician's preference because of its nature as a special 
and invasive adjunctive therapy. The present study demonstrates the lack of clinical 
efficacy of PMXHP when administered for typical SS caused by GNB. We suggest that 
the previously observed effect might be attributable to the Abilene paradox.  
 In 2015, Payen et al. [15] described a non-significant increase in mortality and no 
improvement in organ failure following PMXHP vs. conventional treatment for 
peritonitis-induced SS in the ABDOMIX trial, the latest multicenter randomized control 
trial in France. Although the results of our study were similar to those of the ABDOMIX 
trial, the trials differed in terms of focus, as the latter trial addressed SS due to peritonitis 
in contrast to our study. We note that although most previous reports targeted intra-
abdominal infections, GNB infections occur at a much broader range of sites [11, 14, 22]. 
In principle, PMXHP is only valid for the treatment of bacteremia caused by GNB. 
Accordingly, we selected patients with SS caused by GNB with the prior expectation of 
a high probability of efficacy.  
 In the ABDOMIX trial, randomization was performed at 2 hours after surgery to recruit 
patients with prolonged SS due to peritonitis. Although we initially confirmed SS, this 
 
classification included patients who had emerged from a state of shock at the time of ICU 
admission, according to resuscitation data from this study. However, 66.4% of patients in 
PMXHP group remained in a prolonged state of shock, defined as a mean arterial pressure 
of ≤65 mmHg or hyperlactatemia upon ICU admission. As a result, the mortality rate at 
28 days after ICU admission in our intervention group was 29.1%, similar to that of the 
ABDOMIX study (27.7%).  
 We note that serum endotoxin values were not included among the considerations of 
this study, largely because few facilities have the ability to routinely measure serum 
endotoxin levels, and no standard method has been set for such measurements. We note 
that in this study, GNBs were detected in all patients, and GNB bacteremia accounted for 
approximately 67% of the sepsis cases. This proportion of bacteremia was sufficiently 
higher in comparison with previous reports to ensure that the target population would be 
appropriate even without a measured endotoxin level.  
 PMXHP therapy has not been subjected to a randomized trial in Japan or other 
developed countries. A fair evaluation has thus far been impossible because previous 
reports from Japan have tended to include considerable bias [11], and only the clinical 
 
outcomes of intra-abdominal infection from a nationwide insurance database were 
reported. In 2014, Iwagami et al. [16] reported the mortality rate at 28 days in the presence 
or absence of PMXHP using a propensity score matching analysis. Although that report 
showed a national trend, biological patient information was lacking, and it was necessary 
to add a supplemental study. In contrast, our study presented clear information about the 
patients' medical treatment courses, including vital signs. Although the distributions of 
patient characteristics exhibited considerably heterogeneity, similar to the report by 
Iwagami, the time axis of treatment for SS was maintained in a linear manner. In particular, 
although the initial complications, infection site, and implementation of surgery varied, 
we did not observe a causal relationship between the outcomes after adjusting for 
heterogeneity. Furthermore, we were not able to identify any clinical efficacy of PMXHP, 
despite performing various stratified post-hoc analyses.  
 Previous reports [11] described improvements in oxygenation and blood pressure as 
short-term effects of PMXHP. In this study, although the mean arterial pressure increased 
after the initial PMXHP session relative to the pre-treatment value, the distribution of this 
effect was quite heterogeneous. Therefore, we could not determine whether the observed 
 	
changes were the result of PMXHP or other causes. Similarly, we did not obtain positive 
results regarding the P/F ratio and circulatory failure parameters, which raises concerns 
about the safety of PMXHP therapy. 
 This study has some limitations of note. First, the study design was observational, and a 
case-control design was adopted. Because PMX treatment is already commonly used for 
SS in Japanese healthcare settings, a randomized trial would present ethical challenges. 
To improve the quality of clinical research, however, the present study involved data 
collection and management by an independent clinical research organization to verify the 
likelihood of our interventions and outcomes. Although this was an observational study, 
the registration data at each facility were regularly monitored, and incompatibilities were 
coordinated via feedback as well as in a prospective manner. Second, the PMXHP 
execution rate varied among the participating institutions. However, the average rate of 
32.4% (standard error: 9.7%; range: 0–100%) was acceptable. Although PMXHP itself 
was feasible at the participating hospitals, the policies regarding PMXHP therapy for SS 
ranged from completely negative to active affirmation. Although the overall result might 
have been acceptable, this variability is a source of potential selection bias. Third, the 
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mortality rate used to calculate the sample size [4, 14] differed from the actual number. 
Consequently, the number of samples in the PMXHP group was smaller than the expected, 
thus provided less preferred power. Since the elucidation of the pathophysiology of sepsis, 
the mortality rate associated with sepsis is decreasing [3], and a magic bullet in the form 
of a large difference in mortality might be already out of reach. Accordingly, the hurdles 
that must be overcome to prove the efficacy of a single adjuvant therapy have increased 
in size.  
 In conclusion, no difference in mortality was observed among patients with SS caused 
by GNB, regardless of the implementation of endotoxin adsorption therapy. Accordingly, 
reconfirmation of the efficacy and safety of PMX through a multicenter prospective study 
is essential. 
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Tables and Figures 
Table 1. Comparison between PMXHP group and Conventional group on patient 
characteristic 
Variables 
PMXHP group Conventional group 
P value 
n=134 n=279 
Age, years 70 ± 13 73 ± 12 0.06 
Male / female 63 / 71 153 / 126 0.13 
Pre-existing disease    
 Chronic heart failure 11 (8.2 %) 27 (9.7 %) 0.62 
 Ischemic heart disease 15 (11.2 %) 25 (9.0 %) 0.47 
 Chronic obstructive pulmonary disease 3 (2.2 %) 13 (4.7 %) 0.23 
 Liver cirrhosis 9 (6.7 %) 13 (4.7 %) 0.38 
 Chronic renal failure 3 (2.2 %) 10 (3.6 %) 0.46 
 Diabetes 29 (21.6 %) 59 (21.1 %) 0.90 
 Cancer 10 (7.5 %) 35 (12.5 %) 0.12 
Comorbidities before PMX session    
 ARDS 21 (15.7 %) 42 (15.1 %) 0.87 
 AKI 100 (74.6 %) 173 (62.0 %) 0.01 
 DIC 80 (59.7 %) 115 (41.2 %) <0.01 
Type of infection    
 Community acquired 100 (74.6 %) 197 (70.6 %) 0.39 
 Hospital acquired  30 (22.4 %) 63 (22.6 %) 0.96 
 Healthcare acquired 4 (3.0 %) 19 (6.8 %) 0.11 
Site of infection    
 Pulmonary 13 (9.7 %) 65 (23.3 %) 0.01 
 Intra-abdominal 68 (50.7 %) 89 (31.9 %) <0.01 
 Urinary  37 (27.6 %) 96 (34.4 %) 0.16 
 Soft tissue / skin 6 (4.5 %) 12 (4.3 %) 0.93 
 Other / unknown 10 (7.5 %) 14 (5.0 %) 0.32 
Positive blood culture  88 (65.7 %) 189 (67.7 %) 0.67 
Pathogens    
  E. coli 36 (26.9 %) 82 (29.4 %) 0.59 
 
  Pseudomonas aerginosa 5 (3.7 %) 14 (5.0 %) 0.55 
  Enterobactor spp. 8 (6.0 %) 11 (3.9 %) 0.35 
  Klebsiella spp. 22 (16.4 %) 34 (12.2 %) 0.24 
  Serratia spp. 4 (3.0 %) 5 (1.8 %) 0.43 
  Acinetobactor spp. 3 (2.2 %) 4 (1.4 %) 0.55 
  Citrobactor spp. 3 (2.2 %) 6 (2.2 %) 0.95 
  Gram-positive cocci 4 (3.0 %) 3 (1.1 %) 0.15 
Surgery for infection control, Total 69 (51.5 %) 65 (23.3 %) <0.01 
Laparotomy 53 (39.6 %) 44 (15.8 %) <0.01 
Vital signs at beginning of treatment    
   Mean arterial pressure, mmHg 60 ± 21 59 ± 23 0.98 
   Heart rate, beat/ minutes 114 ± 24 111 ± 27 0.35 
   Respiratory rate, breath/minutes 26 ± 7 26 ± 8 0.71 
   Glasgow coma scale, points 11 ± 4 11 ± 3 0.56 
 Laboratory data    
   C reactive protein, mg/ml 16.5 ± 11.7 15.9 ± 11.8 0.64 
   Lactate, mmol/L 5.0 ± 3.8 4.7 ± 3.9 0.53 
 APACHE  score 26 ± 9 25 ± 9 0.31 
 SOFA score, total score 10.5 ± 3.8 9.5 ± 3.2 <0.01 
Treatment after ICU admission    
 Mechanical ventilation 117 (87.3 %) 184 (65.9 %) <0.01 
 Continuous renal replacement therapy  100 (74.6 %) 63 (22.6 %) <0.01 
 
Data are presented as median values with interquartile range or as number (%). 
Pathogens were detected from blood cultures and contained duplications. 
ARDS: acute respiratory distress syndrome; AKI: acute kidney injury; DIC: 
disseminated intravascular coagulation; APACHE; acute physiology and chronic health 
evaluation; SOFA: sequential organ failure assessment; ECMO : extracorporeal 
membrane oxygenation.  
 
 
Table 2. Primary and secondary outcome 
 
PMXHP group Conventional group 
P value 
n=134 n=279 
 Primary outcome    
  Mortality rate: 28 days after ICU admission 39 (29.1 %) 81 (29.0 %) 0.98 
 Secondary outcomes    
  Mortality rate: Hospital discharge 51 (38.1 %) 69 (34.4 %) 0.68 
  Length of ICU stay, days 8 (4 – 16) 7 (3 - 13) 0.11 
   ICU free days 12 (0 – 20) 15 (0 – 22) 0.16 
  Length of hospital stay, days 26 (11 – 56) 25 (10 - 43) 0.35 
 Duration of mechanical ventilation, days 6 (2 – 13) 3 (0 – 9) <0.01 
 Ventilator free days 16 (0 – 19) 19 (0 – 24) 0.03 
  Comorbidity after PMX session    
ARDS 27 (20.1 %) 27 (9.7 %) <0.01 
AKI 8 (6.0 %) 28 (10.0 %) 0.17 
DIC 31 (23.1 %) 37 (13.3 %) 0.01 
Acute coronary syndrome 1 (0.7 %) 9 (3.2 %) 0.12 
Stroke 1 (0.7 %) 12 (4.3 %) 0.05 
Intraperitoneal abscess 7 (5.2 %) 11 (3.9 %) 0.55 
Data are presented as median values with interquartile range or as number (%). 
ICU: intensive care unit; ARDS: acute respiratory distress syndrome; AKI: acute kidney 
injury; DIC: disseminated intravascular coagulation. 
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Figure 1. Multivariate Cox regression analysis. 
  
 Patients in the polymyxin B hemoperfusion (PMXHP) group received at least one 
session of direct PMXHP as adjuvant therapy for septic shock. 
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Hazard ratio: 0.878
95%CI: 0.619-1.244
P = 0.464 
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Figure 2. Post-hoc analysis. 
  
 The mortality rates at 28 days after ICU admission across the indicated subgroups were 
defined according to several baseline characteristics. PMXHP: polymyxin B immobilized 
fiber hemoperfusion, HR: hazard ratio, CI: confidence interval, AKI: acute kidney injury 
 
 
 
 
0 1 2 3
N HR 95%CI
PMXHP over all 279 0.956 0.654 1.398
Blood culture positive 277 0.853 0.544 1.335
negative 136 1.346 0.653 2.775
Source control surgery yes 134 1.066 0.72 1.578
no 279 0.974 0.701 1.354
Mechanical ventilation yes 301 1.064 0.799 1.415
no 112 1.16 0.685 1.965
Intra-abdominal infection yes 157 0.998 0.718 1.387
no 256 1.048 0.715 1.535
AKI on ICU admission yes 273 0.853 0.634 1.148
no 140 1.32 0.837 2.08
P value for interaction
0.675
0.729
0.665
0.855
0.12
PMXHP better          worse
Hazard ratio
Figure 2
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Chapter 4 
Overall discussion and conclusion 
 In this thesis, the post-marketing study for two medical devices (MDs) is described, 
whose clinical efficacy is skeptical for a long time. The research method used here is 
different for each of the MDs depending on their characteristics. 
 In Chapter 2, the safety and efficacy of the resuscitative endovascular balloon occlusion 
of aorta (REBOA) was examined. Although clinical trials for the catheter used in REBOA 
had been carried out previously, there was no information about the feasibility, efficacy, 
and safety of the therapeutic method. Randomized trial was not needed at the time of 
approval because patients with a severe trunk injury developing hemorrhagic shock were 
distributed to a facility, which could not provide high standard trauma care. Based on this 
background, it was justified that the rare injury is evaluated through advanced treatment 
with a specialized resuscitation team in a single high-volume trauma center. This report 
showed the feasibility of REBOA as a therapeutic strategy, which is the last resort for 
lethal trauma patients. However, we must be prepared for a variety of complications in 
the practice of REBOA. If this information reflected the realistic world of emergency 
 
medicine, it would have been probably a fair result. On the other hand, facilities claim 
that the procedure of REBOA increases the risk. It is an undeniable fact that the procedure 
of REBOA depends on the resuscitation team and not on a single medical person. After 
this report, Inoue et al. reported that the result of the propensity score matched the analysis 
of the Japanese trauma registry data. It has been reported that there has been a serious 
impact on the hospital mortality [1]. Their report showed a relief that the difficulty of 
evaluation of MDs include the entire treatment strategy, which could not be determined 
by measuring only the performance of the product. In the actual resuscitation field, it is 
very difficult for such a progressive treatment to prove superior than the conventional 
method. This clinical report is a case series that proved to be the vanguard in this subject. 
I believe that it played an important role in the clinical evaluation of REBOA, which is 
the current hot topic [2]. 
 In Chapter 3, a multicenter study of an expensive MD has been described; the treatment 
efficacy of this MD has not been proven yet. The history of polymyxin B-immobilized 
fiber hemoperfusionPMXHPtherapy is very long and this therapy is highly popular 
in Japan. Unfortunately, there are only a few low-quality clinical single center reports 
 
available for this therapy, and these clinical evaluations are biased. In view of such a past 
situation, I adopted a multicenter study format, with a focus on the general hospital. In 
addition, I had planned the study in partnership with independent clinical research centers 
to improve the quality of registration data, which usually had a major problem in the 
retrospective study. As a result, the efficacy of the PMXHP therapy with realistic world 
was completely negative. There have been a myriad of development of therapeutic drugs 
and treatments for sepsis till date. However, a potent treatment does not exist. Rapid fluid 
resuscitation, broad-spectrum antibiotics, and appropriate surgical drainage continue to 
be the main steps of sepsis treatment. Though bench data were excellent, these were not 
always effective in bedside. It is not necessary that PMXHP therapy is conducted only as 
part of the complicated septic pathology; in such cases, the clinical efficacy was not 
shown. Despite the observational study, it was possible to collect high-quality data from 
multicenters. I have proven that the medical professional-driven post-marketing study for 
MDs can be realized through this chapter. As these formats for post-marketing clinical 
trials are the most pragmatic ones, it is necessary to develop a platform that can be used 
with simple procedures and reasonable prices in the future. 
  
 It is obvious that the sales strategy of a MD changes over time with new improvements. 
Health care workers, including doctor, nurse, and technician, would begin to use a MD 
without a thorough understanding of the new value. This is a common problem. The 
performance of a MD might have become better, but the clinical effectiveness of the entire 
treatment compared to the conventional treatment is often unclear. Therefore, they are 
always confused in this regard. More than 300,000 MDs are approved in Japan, which is 
huge product pool. It is the responsibility of the hospital management to find the best one 
from this large product line. 
 Though economic analysis was not included in this thesis, I will proceed on the 
effectiveness of MD in the next step. There are many MDs that did not prove to be 
effective as an entire treatment in the area of emergency and critical care medicine. In 
particular, post-marketing study for invasive mechanical ventilator is still untouched 
despite being a device in critical care area. As this subject area is vast, this thesis did not 
have the scope to include all the clinical questions; hence, these will be considered in the 
future research after grasping the current situation. 
 In conclusion, clinical research of the post-marketing study performed in this thesis 
 
would contribute to the safety assurance of MDs in high-risk patients with a severe 
condition. The fair evaluation of MDs by health care worker is sufficiently possible, and 
it calls for a platform with an appropriate scale to resolve a number of clinical questions 
in the realistic medical field. 
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